Site and time of recurrence of advanced cervical cancer

  • Research type

    Research Study

  • Full title

    The site and time of recurence after treatment of advanced stage cervical cancer with chemoradiotherapy versus radiotherapy alone.

  • IRAS ID

    218185

  • Contact name

    Emmanouil Kalampokas

  • Contact email

    emmanouil.kalampokas@nhs.net

  • Sponsor organisation

    NHS Grampian

  • Duration of Study in the UK

    0 years, 11 months, 30 days

  • Research summary

    Cervical cancer (CC) is the third most common leading cause of death from cancer in women worldwide. Radiotherapy (RT) has constituted the preferred modality of treatment for advanced stage CC, or where surgery was not an option, for the past decades.Lack of ability to control pelvic disease for up to 40% of cases, is the leading reason for treatment failure with RT.

    In order to address that problem, a novel treatment has been introduced in 1999 consisting the concurrent use of radiotherapy and chemotherapeutic agents, known as chemoradiotherapy (CRT).

    Many different studies have compared the effectiveness of RT alone versus CRT in terms of overall survival, but to our knowledge the true site and time of recurrence after using RT alone or CRT for the treatment of advanced stage CC has not been established yet.

    The main questions to be answered are what is the site and time of recurrence after using RT alone or CRT for the treatment of advanced stage CC and to assess if there is any difference between the two treatment modalities. Thus, we designed a retrospective study to compare the site and time of recurrence of patients who have been treated with RT or CRT for advanced stage CC.

  • REC name

    West of Scotland REC 3

  • REC reference

    16/WS/0237

  • Date of REC Opinion

    24 Feb 2017

  • REC opinion

    Further Information Favourable Opinion